SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand. (Q48037096)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

0 references

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

15

W R Ballou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

2

D G Heppner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

S Migasena

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

T Chongsuphajaisiddhi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

D M Gordon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P Suntharasamai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

B Permpanich

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A Brockman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P Pitiuttutham

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C Wongsrichanalai

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P Srisuriya

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

B Phonrat

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

K Pavanand

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C Viravan

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 September 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

215-227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Efficacy trial of malaria vaccine SPf66 in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Sex differences in the humoral antibody response to live measles vaccine in young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

A specific T-cell receptor genotype preference in the immune response to a synthetic Plasmodium falciparum malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Comparison of three different schedules of vaccination against hepatitis B in health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Induction of protective immunity against experimental infection with malaria using synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Malaria vaccine trials: SPf66 and all that.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf 66.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

How much malaria is there worldwide?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2897%2900061-2

10.1016/S0001-706X(97)00061-2

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241386%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference